OBJECTIVES: To describe back pain, and HRQoL in postmenopausal women with osteoporosis treated with teriparatide (Forsteo®) in France. METHODS: European, prospective, observational study of 36 months duration (18-month active treatment phase and 18-month post-treatment follow up) in postmenopausal women with osteoporosis who initiated teriparatide. HRQoL measured by EQ-5D and back pain measured by a Visual Analogue Scale (VAS) and a questionnaire were collected at each follow-up visit. RESULTS: Among 309 patients enrolled in France (18.8% of the total EFOS cohort), 290 (94.5%) had any follow-up data, and 201 (65.0%) completed the last post-treatment visit. At baseline, patients were 73.8 (7.4) years old (mean (SD)), 98.6% of patients had 2 or more fractures after age 40 years, the mean (SD) number of fractures was 4.2 (1.7) and median number was 4.0 (interquartile range 3.0 – 5.0). During the study, the mean (SD) duration of treatment by teriparatide was 443 (203) days; at the end of 17th month, 67.9% of patients were still on treatment. The main reasons of treatment discontinuation were treatment completion (69.9%), adverse events (14.5%), patient decision (14.0%), and physician decision (2.2%). Between baseline and end of study, the rate of women with back pain decreased from 93.8% to 83.3% and 57.1% had an improvement in the severity, mean (SD) back pain intensity VAS decreased from 55.9 (24.8) to 35.0 (24.2), and mean (SD) EQ-5D VAS increased from 52.6 (19.4) at baseline to 57.8 (21.4) at end of study. CONCLUSIONS: French patients with severe osteoporosis treated with teriparatide in a routine setting had an increase in quality of life and a decrease in back pain during the teriparatide treatment period and post-treatment follow-up. The results should be interpreted in the context of a non-controlled observational study.